All cataloged matching companies in this field are shown below. Expand filters to narrow the results.
Disease tags identify mentions in recorded facts or pipeline text, not approved indications or a complete pipeline. Platform service providers may have no disease-specific tag.
74 matching companies
On 2026-05-01, FDA approved vepdegestrant for certain ESR1-mutated ER+/HER2- advanced breast cancers. In August, the company reported completion of a global license to Rigel and expected future data from three Phase 1 programs.
The 2026-10-29 announcement places KT-621 in Phase 2 for AD and asthma and reports Phase 1 healthy-volunteer results for KT-579. Sanofi is advancing KT-485 in Phase 1; Gilead is preparing a KT-200 CDK2 molecular glue IND.
Original Haisco disclosures identify HSK29116 as an oral BTK PROTAC; the NCI Drug Dictionary specifies CRBN recruitment.
Gilead's pipeline updated 2026-10-29 lists GS-6791 as a Phase 1 IRAK4 degrader for inflammatory diseases. Nurix's 2026-10-05 announcement confirms its oral route and clinical status.
An original Phase 1 DKY709 abstract at AACR 2026 describes an oral IKZF2 molecular glue and reports human pharmacodynamic, PK, and preliminary efficacy data through 2024-09-05.
MSD's website records joint clinical development of an MGD candidate with Degron on 2026-05-21. Original MSD / Proxygen announcements describe a multi-target molecular glue collaboration. C4's 2026 SEC filing states that MSD's DAC agreement ended in November 2025.
The website lists DEL/ASMS ligand discovery, linker design, binary / ternary binding, ubiquitination, HiBiT/NanoBRET, and in vivo PK/PD services.
The 2026-10-12 announcement reports the first participant enrolled in Phase 3 DAYBreak CLL-306. NX-5948 is an oral, brain-penetrant BTK degrader. The company also reported collaboration progress with Roche, Gilead, Pfizer, and Sanofi.
AC699 (also called AC0699 on the website) is an oral ERα chimeric degrader. Phase 1 human results and FDA Fast Track were reported in 2024.
A dedicated PROTAC / molecular glue page lists protein production, crystallography, screening, binding kinetics, drug metabolism, bioassays, and AIDD/CADD, plus custom PROTAC design and synthesis.
An April 2026 announcement reports first dosing in Phase 3 setidegrasib/ASP3082 for pancreatic cancer. A Japanese official registry also records first dosing in NSCLC Phase 3 in August 2026.
The company describes AUTAC as comprising an autophagy-recruiting group, target ligand, and linker. Its website does not list named candidates or clinical stages.
The original 2022 study demonstrated the p62-mediated AUTOTAC platform. A 2026 investigator conference abstract still describes IND-enabling preclinical work in neurodegenerative disease.
PAQ develops KRAS degraders. The registered Phase 1 PT0253 study is in advanced solid tumors with KRAS G12D mutations. Historical autophagy positioning was not substituted for current technical disclosures.
The company explicitly supports PROTACs, hydrophobic tags, and molecular glues through FFS, FTE, and integrated discovery models, including target engagement, ubiquitination, proteasome dependence, and bioanalysis.
The 2026-08-11 announcement reports ongoing Phase 2 MOMENTUM and Phase 1b cemsidomide plus elranatamab studies. Phase 1 results were announced in June. A 2026 quarterly report describes other platform collaborations; MSD's DAC agreement ended in November 2025.
The website reports Novartis licensing of the VAV1 molecular glue MRT-6160 and Phase 2 studies. The NEK7 molecular glue MRT-8102 completed Phase 1 GFORCE-1; MRT-2359 is in clinical combination development.
The website defines PLX-61639 as an oral, selective, monovalent SMARCA2 direct degrader and lists its clinical study. PLX-66140 is a CDK2 CRBN molecular glue.
The 2026-02-03 announcement reports first dosing in the Phase 1/2 NEO-811 renal cancer trial. The company pipeline identifies ARNT/HIF-1β as its target and lists pharmaceutical collaborations.
The website describes ORICISION as discovering both protein degraders and conformational correctors, emphasizing patient-derived models and clearance of disease-associated proteins.
AMX-883, first dosed in October 2026, is a DCAF16-mediated BRD9 Targeted Glue. The company previously disclosed collaborations with BMS and Merck KGaA.
An original 2026 ASCO abstract by company researchers describes CT-01 as a GSPT1/NEK7 dual-target molecular glue. Phase 1 began in May 2025, studying monotherapy and combination with everolimus in hepatocellular carcinoma.
The current website focuses on covalent chemistry and ALS / Parkinson's programs. An original 2021 announcement records a four-target Novartis collaboration.
The website describes EPI-326 as a tissue-selective EGFR bispecific antibody degrader in an ongoing Phase 1 NSCLC/HNSCC trial, NCT07462377.
An October 2026 SEC filing reports preliminary human IgE reduction in Phase 1 for the IgE cataLYTAC LCA-0061. Phase 1 LCA-0321 in Graves' disease is ongoing; LCA-0062 is in IND preparation.
A 2026-10-08 website announcement describes a preclinical sFlt1 ATAC for preeclampsia. ATAC uses ASGPR to route extracellular target proteins into hepatocyte lysosomes.
A 2026-06-23 announcement states that TRIM21 E3-associated TRIMTAC/TRIMGLUE selectively degrade toxic aggregates and oligomers while sparing functional monomers, in early portfolio development.
The website and 2026 ASCO materials identify ST-01156 as an RBM39 molecular glue degrader in Phase 1 studies in solid tumors including Ewing sarcoma and hepatocellular carcinoma.
The website describes covalent p300 molecular glues and Cyclin K degradation-mediated CDK12 regulation. An April 2026 announcement advances two MGD pipelines toward development candidates and IND preparation while expanding nondegradative induced proximity.
A March 2026 announcement reports the first patient treated in Phase 1/2 TRI-611. A September 2026 Nature paper describes its distinctive ALK–CRBN interface and preclinical intracranial tumor models.
A May 2026 announcement reports PK, PBMC degradation, and early activity in Phase 1 dose escalation of the bifunctional CDK4/6 degrader BTX-9341; expansion studies are ongoing.
A 2026-10-29 announcement reports Phase 3 BHV-1300 recruiting in Graves' disease and licensing of part of the Asian MoDE pan-IgG portfolio to Ono. Phase 3 BHV-1400 was still planned at that time.
The website describes CT7439 as both a CDK12/13 inhibitor and Cyclin K glue degrader. Its Phase 1/2 trial, NCT06600789, uses oral capsules.
An original 2026-08-13 Photys / Polymed announcement reports Phase 1 healthy-volunteer dosing of PHT-776/HPB-143. Photys holds rights outside Greater China and Southeast Asia.
A 2026-06-16 Rigel announcement confirms completion of an exclusive global development, manufacturing, and commercialization license for VEPPANU from Arvinas/Pfizer, effective 2026-06-11.
An October 2025 company announcement and original structural study establish DCAF2 as an E3 for PROTAC-mediated degradation. This does not make the company's other clinical small molecules degraders.
Gyre completed its acquisition of Cullgen on 2026-05-04; they are consolidated into one company record.
CHAMP-1 is a Phase 1/2 RNK05047 study. The study center's description specifies BRD4 clearance and intravenous administration.
The website identifies HP518 as an oral AR PROTAC. Enrollment in China Phase 2 is complete, Australian Phase 1 is complete, and China combination Phase 1/2 authorization was obtained in November 2025.
A May 2026 financing announcement describes DEG6498 as an oral HuR molecular glue inducing a CRBN–HuR interaction. First dosing occurred in November 2025; Phase 1 dose escalation is ongoing.
The Degraducer website specifies bifunctional linkers and a ubiquitin–proteasome mechanism. Lead asset UBX-303-1 targets BTK.
An original 2026 ASCO abstract describes PIN-5018 as an oral CRBN-mediated CK1α molecular glue. The first Phase 1 cohort completed without DLTs; subsequent cohorts are enrolling.
The website lists a selective heterobifunctional p300 degrader as IND-enabling. PVTX-321 ER and PVTX-405 IKZF2 molecular glues are ready for GLP toxicology scale-up.
A July 2026 patent announcement explicitly identifies FIM-001 as an IRAK-M degrader still in preclinical development.
The website lists GLB-001 Phase 1 in U.S. AML/HR-MDS and Chinese myeloid tumors, and GLB-002 Phase 1 in Chinese NHL.
The website lists CaDAnCe-302 for tacabrutideg/BGB-16673 as Phase 3. CDAC is the company's term for chimeric degradation-activating compounds.
GT20029 is a topical AR PROTAC. A 2024 announcement reports that the China Phase 2 male androgenetic alopecia study met its primary endpoint.
An original 2025 ESMO abstract describes QLH12016 as an oral AR PROTAC, with data through February 2025 from 36 patients with mCRPC.
An April 2025 website announcement identifies TQB3019 as the OAPD platform's first oral BTK PROTAC and reports Chinese clinical authorization.
The official pipeline explicitly lists HJ-002 and HJ-004 as EGFR PROTACs for NSCLC and advanced cancers, respectively.
The website lists NanoBRET/TR-FRET/SPR and HiBiT/JESS platforms for permeability, target engagement, ternary complexes, and quantitative degradation kinetics.
A dedicated page describes E1/E2/E3 and deubiquitinase assays for the ubiquitin–proteasome system, plus PROTAC evaluation from ternary complexes to degradation kinetics and selectivity.
CHARMED provides parallel synthesis with common E3 ligands and linkers, degradation screening, and early ADME. The website identifies an SHP2 degrader collaboration with Japan's UBE.
An official technical poster describes development of bifunctional degraders using novel E3 ligases and construction of molecular glue libraries.
The website offers CRBN/VHL/IAP degrader design and synthesis, binary / ternary binding, NanoBRET, HiBiT, ubiquitination, and direct-to-biology workflows, and lists a collaboration with Amphista.
The company explicitly accepts FFS, cost-sharing, and FTE models. Its dedicated page lists validated assays for BRD4, KRAS, CRBN/VHL binding, and ternary complexes.
The website explicitly offers PROTAC and molecular glue screening and drug discovery support, describing assay systems for degradation research.
A dedicated R&D Systems page explicitly offers custom active-degrader design / synthesis, building-block panels, and E3 ligase development, including a Tocris client case.
On 2026-08-13, FDA granted accelerated approval to iberdomide (Zenbexus) with daratumumab/hyaluronidase-fihj and dexamethasone for certain previously treated multiple myeloma patients. It is a CRBN-modulating CELMoD.
On 2026-06-08, Roche announced joint development and commercialization with Nurix of the oral BTK degrader bexobrutideg (NX-5948), with CLL Phase 3 planned for summer 2026.
Kymera's Q2 2026 update reports that Sanofi began first-in-human Phase 1 KT-485 (SAR447971), an oral IRAK4 degrader, in June. Sanofi is responsible for subsequent development, regulatory work, and commercialization.
DT2216 is a VHL-recruiting BCL-XL PROTAC. An original 2025 Phase 1 paper in 20 patients reports human PK and peripheral leukocyte BCL-XL reduction. NCI lists combination studies in ovarian and fibrolamellar liver cancers.
An original joint announcement with Photys on 2026-08-13 reports Phase 1 healthy-volunteer dosing of HPB-143/PHT-776. Polymed licensed development and commercialization rights outside Greater China and Southeast Asia to Photys.
An original Nurix announcement on 2026-09-29 reports a research milestone in the Pfizer DAC collaboration. Pfizer handles antibody conjugation and subsequent development. Global vepdegestrant development, manufacturing, and commercialization rights transferred to Rigel in June 2026.
Lilly's website lists LY4584180 as an oral, monovalent BCL6 polymerizing molecular glue. Phase 1 NOVA-BCL6-1, NCT07226843, is recruiting; UCSF's trial page records an April 2026 start.
A dedicated official page offers PROTAC and partial-PROTAC synthesis, E3 ligand / linker design, molecular glues, ternary-complex and cellular degradation evaluation, and custom ADME/PK and toxicology services, through standalone or integrated projects.
The official custom synthesis page explicitly lists molecular glue libraries and bifunctional compounds including PROTACs, with FTE quotations and IP-sensitive work under confidentiality agreements.
Almac Discovery's current official pipeline lists an oral GSPT1 molecular glue and a GSPT1 degrader–antibody conjugate, both preclinical. DAC payloads are used in HER2/CD33-targeted constructs.
The group website lists TPD as a CRO service. Custom offerings explicitly cover target engagement, modulation, and degradation, plus custom proteins, cell lines, and assay development.
The website explicitly offers PROTAC and molecular glue screening, including HiBiT, proteomics, ternary-complex structures, ADME/DMPK, in vivo formulations, and safety services.
An official page explicitly offers ligand / linker design, ternary-complex prediction, mechanism / selectivity evaluation, DMPK, early CMC, solubility, crystallization, and formulation strategies.
The service page covers target / E3 ligand discovery, linker optimization, SPR/ITC, ubiquitination and degradation assays, and custom ADME and PBPK modeling.
The integrated PROTAC offering brochure lists medicinal chemistry, bioassays, solubility / permeability / stability, PK/PD, in vivo pharmacology, safety, and toxicology, supporting lead optimization through candidate selection.
A dedicated page describes linker / ligand synthesis, biophysical and cellular degradation evaluation, PK/PD, toxicology, IND support, and DAC services.
Coverage expands from sourced records; this database does not claim all biopharma companies.
